Erratum: Characterisation of patients with interstitial pneumonia with autoimmune features (European Respiratory Journal (2016) 47 (1767–1775) DOI: 10.1183/13993003.01565-2015);Characterisation of patients with interstitial pneumonia with autoimmune features

European Respiratory Journal

Volumn 47, Issue 6, 2016, Pages 1767-1775

  Oldham, Justin M ^a,e   Adegunsoye, Ayodeji ^b   Valenzi, Eleanor ^b   Lee, Cathryn ^b   Witt, Leah ^b   Chen, Lena ^b   Husain, Aliya N ^b   Montner, Steven ^b   Chung, Jonathan H ^b   Cottin, Vincent ^c   Fischer, Aryeh ^d   Noth, Imre ^b   Vij, Rekha ^b   Strek, Mary E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITÉ LYON 1   (France)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; INTERSTITIAL PNEUMONIA WITH AUTOIMMUNE FEATURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOGRAPHY; SEROLOGY; SEX DIFFERENCE; SURVIVAL; AGED; AUTOIMMUNE DISEASE; BIOPSY; COHORT ANALYSIS; COMPARATIVE STUDY; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME;

IMMUNOSUPPRESSIVE AGENT;

AGED; AUTOIMMUNE DISEASES; BIOPSY; COHORT STUDIES; CONNECTIVE TISSUE DISEASES; FEMALE; HUMANS; IDIOPATHIC INTERSTITIAL PNEUMONIAS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84973473707     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.51565-2015     Document Type: Erratum

References (24)

1. de Lauretis A, Veeraraghavan S, Renzoni E. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis 2011; 8: 53-82.
2. Fischer A, West SG, Swigris JJ, et al. Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest 2010; 138: 251-256.
3. Corte TJ, Copley SJ, Desai SR, et al. Significance of connective tissue disease features in idiopathic interstitial pneumonia. Eur Respir J 2012; 39: 661-668.
4. Kinder BW, Collard HR, Koth L Jr, et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med 2007; 176: 691-697.
5. Vij R, Noth I, Strek ME. Autoimmune-featured interstitial lung disease: a distinct entity. Chest 2011; 140: 1292-1299.
6. Omote N, Taniguchi H, Kondoh Y, et al. Lung-dominant connective tissue disease: clinical, radiologic and histologic features. Chest 2015; 148: 1438-1446.
7. Fischer A, Antoniou KM, Brown KK, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015; 46: 976-987.
8. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
9. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733-748.
10. Lynch DA Nonspecific interstitial pneumonia: evolving concepts. Radiology 2001; 221: 583-584.
11. Steen VD, Lucas M, Fertig N, et al. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody. J Rheumatol 2007; 34: 2230-2235.
12. Solomon JJ, Olson AL, Fischer A, et al. Scleroderma lung disease. Eur Respir Rev 2013; 22: 6-19.
13. Raghu G, Lynch D, Godwin JD, et al. Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. Lancet Respir Med 2014; 2: 277-284.
14. Ferri C, Manfredi A, Sebastiani M, et al. Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: Our interdisciplinary rheumatology-pneumology experience, and review of the literature. Autoimmun Rev 2016; 15: 61-70.
15. Assayag D, Kim EJ, Elicker BM, et al. Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria. Respir Med 2015; 109: 1326-1331.
16. Kim HC, Ji W, Kim MY, et al. Interstitial pneumonia related to undifferentiated connective tissue disease: pathologic pattern and prognosis. Chest 2015; 147: 165-172.
17. Strand MJ, Sprunger D, Cosgrove GP, et al. Pulmonary function and survival in idiopathic vs secondary usual interstitial pneumonia. Chest 2014; 146: 775-785.
18. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156: 684-691.
19. Ryerson CJ, Vittinghoff E, Ley B, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest 2014; 145: 723-728.
20. Oldham JM, Kumar D, Lee C, et al. Thyroid disease is prevalent and predicts survival in patients with idiopathic pulmonary fibrosis. Chest 2015; 148: 692-700
21. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-2666.
22. Kim EJ, Collard HR, King TE Jr Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest 2009; 136: 1397-1405.
23. Mileti LM, Strek ME, Niewold TB, et al. Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experience. J Clin Rheumatol 2009; 15: 254-255.
24. Parambil JG, Myers JL, Lindell RM, et al. Interstitial lung disease in primary Sjogren syndrome. Chest 2006; 130: 1489-1495.